Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Hutchmed China Ltd ADR (NQ: HCM ) 19.04 +0.62 (+3.37%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Hutchmed China Ltd ADR < Previous 1 2 3 4 5 6 7 8 Next > 10 Stocks Reacting To April PCE: Marvell Technology Leads The Rally May 26, 2023 Via Benzinga Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review May 25, 2023 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting May 25, 2023 From HUTCHMED (China) Limited Via GlobeNewswire Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing May 18, 2023 Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com From Virtual Investor Conferences Via GlobeNewswire HUTCHMED Announces Board of Directors and Board Committee Membership May 12, 2023 From HUTCHMED (China) Limited Via GlobeNewswire International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023 May 15, 2023 From Virtual Investor Conferences Via GlobeNewswire HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees May 10, 2023 From HUTCHMED (China) Limited Via GlobeNewswire International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023 May 09, 2023 From Virtual Investor Conferences Via GlobeNewswire HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer April 17, 2023 From HUTCHMED (China) Limited Via GlobeNewswire Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday April 13, 2023 U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session. Via Benzinga HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023 April 11, 2023 From HUTCHMED (China) Limited Via GlobeNewswire Intended Retirement of Independent Non-executive Director April 11, 2023 From HUTCHMED (China) Limited Via GlobeNewswire Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal April 08, 2023 Duality Biologics out-licensed global rights (ex-China) for two ADC candidates to BioNTech, Pfizer’s partner, for one of the two original COVID-19 vaccines in a deal worth $170 million upfront and up... Via Talk Markets Why Levi Strauss Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session April 06, 2023 Gainers Liquid Media Group Ltd. (NASDAQ: YVR) jumped 88.1% to $0.2719. Via Benzinga Lamb Weston, TH International, AMC Entertainment And Other Big Stocks Moving Higher On Thursday April 06, 2023 U.S. stocks traded lower, with the Dow Jones falling around 100 points on Thursday. Here are some big stocks recording gains in today’s session. Via Benzinga Why Bullfrog AI Holdings Shares Are Trading Higher By 73%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session April 04, 2023 Gainers Secoo Holding Limited (NASDAQ: SECO) shares surged 138% to $1.43. Via Benzinga Why Is HUTCHMED Stock Trading Higher Today? April 04, 2023 HUTCHMED (China) Limited (NASDAQ: HCM) shares are trading higher on Tuesday after the company initiated enrollment registration for its ongoing Phase 2 trial of HMPL-453 for intrahepatic... Via Benzinga HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations April 04, 2023 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer March 30, 2023 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China March 14, 2023 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED Confirms No Assets Held at Silicon Valley Bank March 12, 2023 From HUTCHMED (China) Limited Via GlobeNewswire Why Miromatrix Medical Shares Are Trading Lower By 40%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session March 08, 2023 Gainers Kimball International, Inc. (NASDAQ: KBAL) shares jumped 84.9% to $12.40 after HNI Corporation announced it will acquire the company for $485 million. Via Benzinga 12 Health Care Stocks Moving In Wednesday's Intraday Session March 08, 2023 Via Benzinga HUTCHMED Reports 2022 Full Year Results and Provides Business Updates February 28, 2023 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED Completes Patient Enrollment of Phase II Registration Trial of Amdizalisib in Follicular Lymphoma in China February 27, 2023 From HUTCHMED (China) Limited Via GlobeNewswire Why Hempacco Are Trading Lower By 58%? Here Are Other Stocks Moving In Friday's Mid-Day Session February 10, 2023 Gainers SeqLL Inc. (NASDAQ: SQL) shares jumped 120% to $1.85 after dropping around 39% on Thursday. SeqLL recently announced the establishment of a two-year Cooperative Research and Development... Via Benzinga Lyft, BARK And Other Big Stocks Moving Lower In Friday's Pre-Market Session February 10, 2023 U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. Via Benzinga HUTCHMED to Announce 2022 Final Results January 31, 2023 From HUTCHMED (China) Limited Via GlobeNewswire Dada Nexus, Bilibili And Other Big Stocks Moving Lower On Monday January 30, 2023 U.S. stocks traded lower, with the Nasdaq Composite dropping over 100 points on Monday. Here are some big stocks recording losses in today’s session. Via Benzinga Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug January 28, 2023 Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion,... Via Talk Markets < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.